Neumora Therapeutics Inc NMRA
About Quantitative Ratings
Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with quantitative ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating.
Is it the right time to buy, sell, or hold?
Start a free trial of Morningstar Investor to unlock exclusive ratings and continuous analyst coverage to help you decide if NMRA is a good fit for your portfolio.
News
-
Neumora Shares Slide Premarket as FDA Puts Early Study of Schizophrenia Drug on Hold
-
Neumora Therapeutics Announces Clinical Hold of Phase 1 NMRA-266 Study
-
Neumora Therapeutics to Participate at Stifel 2024 Virtual CNS Days
-
Neumora Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business Update
-
Amgen discloses more than $400 million stake in recent IPO Neumora Therapeutics
Trading Information
- Previous Close Price
- $9.06
- Day Range
- $8.82–9.31
- 52-Week Range
- $8.82–21.00
- Bid/Ask
- $7.25 / $9.16
- Market Cap
- $1.45 Bil
- Volume/Avg
- 677,291 / 586,035
Key Statistics
- Price/Earnings (Normalized)
- —
- Price/Sales
- —
- Dividend Yield (Trailing)
- —
- Dividend Yield (Forward)
- —
- Total Yield
- —
Company Profile
Neumora Therapeutics Inc is a clinical-stage biopharmaceutical company founded to confront the global brain disease crisis by taking a fundamentally different approach to the way treatments for brain diseases are developed. It has rapidly scaled its therapeutic pipeline, which currently consists of seven clinical and preclinical neuroscience programs that target novel mechanisms of action for a broad range of underserved neuropsychiatric disorders and neurodegenerative diseases. The company expects to continue to progress in the development of its pipeline with the planned initiation of multiple clinical trials across its programs over the next 12 to 18 months, which supports numerous anticipated data readouts.
- Sector
- Healthcare
- Industry
- Biotechnology
- Stock Style Box
- —
- Total Number of Employees
- 124
- Website
- https://www.neumoratx.com
Valuation
|
Metric
|
NMRA
|
|---|---|
Price/Earnings (Normalized) | — |
Price/Book Value | 3.10 |
Price/Sales | — |
Price/Cash Flow | — |
Price/Earnings
No chart available
Financial Strength
|
Metric
|
NMRA
|
|---|---|
Quick Ratio | 18.12 |
Current Ratio | 19.05 |
Interest Coverage | — |
Quick Ratio
NMRA
Profitability
|
Metric
|
NMRA
|
|---|---|
Return on Assets (Normalized) | −48.67% |
Return on Equity (Normalized) | −4,159.52% |
Return on Invested Capital (Normalized) | −1,961.33% |
Return on Assets
NMRA
Biotechnology Industry Comparables
|
Ticker
|
Name
|
Morningstar Rating for Stocks
|
Capital Allocation
|
Economic Moat
|
Market Cap
|
|---|---|---|---|---|---|
NVO
| Novo Nordisk A/S ADR | Zdkrbmxrm | Mdlyj | $554.7 Bil | |
VRTX
| Vertex Pharmaceuticals Inc | Qljhrdbrv | Wcgvj | $102.7 Bil | |
REGN
| Regeneron Pharmaceuticals Inc | Rdplhmc | Jflsv | $97.8 Bil | |
MRNA
| Moderna Inc | Gcdqxsy | Pljht | $41.3 Bil | |
ARGX
| argenx SE ADR | Vpgbwqxz | Drcf | $22.3 Bil | |
BNTX
| BioNTech SE ADR | Cvgndhzp | Ylldk | $21.0 Bil | |
ALNY
| Alnylam Pharmaceuticals Inc | Ktkhzpn | Ghfngl | $18.2 Bil | |
BMRN
| Biomarin Pharmaceutical Inc | Jyxxrkjkd | Wqcybz | $15.4 Bil | |
RPRX
| Royalty Pharma PLC Class A | Zqswbjngr | Dkxxrj | $12.5 Bil | |
INCY
| Incyte Corp | Lzbjqcwxg | Yqfrwj | $11.6 Bil |